SYSTEMIC JIA FOUNDATION

NEXTGEN 2026 | STILL'S DISEASE & MAS

November 6–7, 2026 • Hilton Orlando, Orlando, Florida • DRAFT PROGRAM

All times Eastern (Orlando). Talk allocations include 1 minute for speaker transitions. Talks are intentionally short to leave time for discussion.

FRIDAY · NOVEMBER 6

8:00am-8:30am	**Breakfast**	
8:30am-8:40am	**Welcome & Brief Goals of NextGen 2026**	
	Rashmi Sinha	
8:40am-9:15am	**Patient Voices Session**	
	Patient Voices	Jodi Plont; Candi Tambwe & Channing Russell; Karrah Washington (virtual); Patient (China; virtual)
9:15am-10:30am	**Difficult-to-Treat Still's Disease**	
9:15–9:21	**Alexei Grom**	Managing Refractory Still's Disease: From MAS to Lung Disease & Persistent Arthritis
9:21–9:27	**Susan Shenoi**	Clinical Management of Refractory Still's Disease: My experience at Seattle Children's
9:27–9:33	**Bruno Fautrel**	Difficult to Treat or Difficult to Manage Still's Disease: Do We Need to Define It?
9:33–9:39	**Michael Ombrello**	Type I Interferon-High Still's: A Distinct Subgroup?
9:39–9:45	**Mariana Marques**	Can JAK Inhibitors Replace Biologics in Refractory Still's?
9:45–9:51	**Melissa Hines (virtual)**	Ruxolitinib in Severe Hyperinflammation: How Much Is Enough?
9:51–10:30		*Open Discussion*
	5-minute break	
10:35am-11:30am	**A targeted therapy for MAS: From Clinical Trials to Real-World Practice**	
	Moderated by: Fabrizio De Benedetti	
	Patient Voices	Janine Kelly (virtual); Zulayka Martinez (virtual)
10:35–10:41	**Alexei Grom**	Lessons from the MAS clinical development program for emapalumab
10:41–10:47	**Brian Jamieson**	Emapalumab in the US: Early Uptake, Treatment Patterns & Access
10:47–11:30		*Open Discussion with speakers & FDA participants: Emily C. Gotschlich, Carrie Diamond (virtual), & Elizabeth Hart*
11:30am-12:00pm	**Treating MAS When Targeted Therapies Are Unavailable: What Might Work Best?**	
11:30–11:36	**Narendra Bagri**	Treating MAS with Limited Therapies: Experience from a Public Hospital in India
11:36–11:42	**Daniela Piotto**	Treating MAS with Limited Therapies: Experience from a Public Hospital in Brazil
11:42–12:00		*Open Discussion with speakers, Alexei Grom, & Fabrizio De Benedetti: practical MAS treatment approaches*
12:00pm-1:05pm	**Group Photo & Lunch**	
1:05pm-2:10pm	**Emerging Therapies 1: New Targets & Next-Generation IL-1 Inhibitors**	
	Moderated by: Scott Canna	
	Part 1: New Approaches to MAS & Hyperinflammation	
1:05–1:11	**Swaminathan P. Iyer**	ELA026 in Secondary HLH: Clinical Evidence & Implications for MAS
1:11–1:17	**Isaac Meng**	Targeting GM-CSF from MAS to Still's Disease & Beyond
1:17–1:23	**Hung-Kai Kevin Chen**	Indemakitug: Advancing Interferon-γ Blockade for HLH/MAS

	Part 2: Expanding IL-1 Treatment Options for Still's Disease	
1:23–1:29	**Guliang Xia**	GenSci161: Mechanism & Therapeutic Rationale for Dual IL-1α/IL-1β Inhibition
1:29–1:35	**Caifeng Li**	IL-1β Blockade in Systemic JIA: Phase II Clinical Trial Results with Firsekibart
1:35–2:10		*Open Discussion with speakers & FDA participants Raj Nair & Emily C. Gotschlich*
2:10pm-2:40pm	**Treating MAS When Targeted Therapies Are Unavailable: What Might Work Best?**	
2:10–2:16	**Narendra Bagri**	Treating MAS with Limited Therapies: Experience from a Public Hospital in India
2:16–2:22	**Daniela Piotto**	Treating MAS with Limited Therapies: Experience from a Public Hospital in Brazil
2:22–2:40		*Open Discussion with speakers, Alexei Grom, & Fabrizio De Benedetti: practical MAS treatment approaches*
2:40pm-3:05pm	**Cellular Therapies for SJIA**	
2:40–2:47	**Holly Wobma (virtual)**	CAR-Tregs & Beyond: New Cellular Approaches to Treating Arthritis & Still's Disease
2:47–2:52	**Grant Schulert**	Which Immune Cells Should We Target in Still's Disease & MAS?
2:52–3:05		*Open Discussion*
3:05pm-4:20pm	**HSCT in Refractory Still's Disease: Who, When, & What About Arthritis?**	
	Moderated by: Rebecca Marsh	
3:05–3:16	**Patient Voices**	Experiences with HSCT
3:16–3:22	**Shan Chandrakasan**	HSCT for Still's Disease & MAS: Our Experience at Emory
3:22–3:28	**Sharat Chandra**	HSCT for Refractory Still's Disease & Lung Disease: Our Experience at CCHMC
3:28–3:34	**Julie Barsalou (virtual)**	HSCT for Refractory Still's Disease: Lessons from Three Patients at CHU Sainte-Justine
3:34–3:40	**Lauren Henderson**	Persistent Arthritis in Still's Disease: T-Cell Biology & Clinical Implications for HSCT?
3:40–3:48	**Grant Schulert**	A Rheumatologist's Perspective on HSCT in Refractory Still's Disease
3:48–4:20		*Open Discussion*
4:20pm-4:40pm	**Open Floor: Where the Conversation Takes Us**	
4:40pm-5:40pm	**Parallel Working Meetings**	
	Working Groups	HSCT; weaning guidance; MAS without targeted therapies
5:40pm-6:00pm	**Working Groups Report Back**	
6:40pm-10:00pm	**Networking Reception + Dinner (Cuba Libre Restaurant)**	
SATURDAY · NOVEMBER 7		
8:00am-8:30am	**Breakfast**	
8:30am-8:40am	**Welcome & Plan for the Day**	
8:40am-8:48am	**Patient Voices**	Brittany Franklin: Trial Design for Rare Inflammatory Diseases: A Parent's Perspective
8:48am-9:15am	**Fireside Chat: The Future of Still's Drug Development**	
	Fabrizio De Benedetti & Raj Nair	Fireside discussion
9:15am-9:30am	**Emerging MAS Therapies: Follow-Up from Day 1**	
9:15–9:22	**Qiong Fu**	Lower-dose emapalumab in refractory MAS: Experience from China
9:22–9:30	**Qiong Fu**	GM-CSF Inhibition in Still's Disease: Results from a Phase II Clinical Trial
9:30am-10:40am	**Improving Global Access to Still's Disease & MAS Therapies**	
9:30–9:40	**Patient Voices**	Sarah Prado; Alok Patro (virtual)

9:40–9:46	**Francesca Minoia**	What the METAPHOR Study Reveals About Global Disparities in Treatment Access
9:46–9:52	**Luciana Pereira**	From Approval to Access: The Reality for Patients in Brazil
9:52–10:00	**A. V. Ramanan**	Biosimilars in Pediatric Rheumatology: What Have We Learned, and Could IL-1 Be Next?
10:00–10:40		*Open Discussion with speakers, Narendra Bagri, Daniela Piotto & FDA participants Juwaria Waheed & Raj Nair*
	5-minute break	
10:45am-11:50am	**Treating to Target & Weaning Therapy After Disease Control**	
	Moderated by: Lauren Henderson	
10:45–10:55	**Patient Voices**	Marta Mendes; Hanyi Chrisman
10:55–11:02	**Scott Canna**	IL-18 & Other Biomarkers: Setting the Stage for Targeted Therapies
11:02–11:07	**Claudia Bracaglia**	Is the Immune System Really Back to Normal After Clinical Control?
11:07–11:12	**Bella Mehta**	What Works with Weaning in Clinical Practice with Adults
11:12–11:17	**Bas Vastert**	Toward IL-18-Guided Treatment: Personalizing Therapy in Still's Disease
11:17–11:50		*Open Discussion*
11:50am-12:50pm	**Lunch & Open Floor**	
12:50pm-1:55pm	**Emerging Therapies 2: Targeting Inflammasome & IL-18**	
12:50–12:58	**Rebecca Coll (virtual)**	Targeting the Inflammasome: Emerging Therapies & Unanswered Questions
12:58–1:04	**Rebecca Marsh (virtual)**	IL-18 Blockade: Evidence in NLRC4/XIAP and Beyond
1:04–1:10	**Eduardo Schiffrin**	Tadekinig Alfa: Development & Regulatory Update
1:10–1:16	**Scott Canna**	MAS825: Compassionate-Use Experience in Refractory Still's Disease
1:16–1:22	**Mona Trivedi**	MAS825: Future Clinical Development
1:22–1:55		*Open Discussion with speakers & FDA participants Raj Nair & Emily C. Gotschlich*
1:55pm-2:50pm	**Parallel Working Meetings**	
	Working Groups	HSCT; MAS without targeted therapies; JAK inhibitors
2:50pm-3:20pm	**Groups Report Back**	
3:20pm-3:30pm	**Conference Wrap-Up**	

Thanks to Our Sponsors: Sobi, Sanofi & Electra Therapeutics

See you in Orlando!